IgE-based immunotherapy of cancer: challenges and chances

Authors

  • J. Singer,

    1. Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria
    Search for more papers by this author
  • E. Jensen-Jarolim

    Corresponding author
    1. Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria
    2. Comparative Medicine, Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria
    • Correspondence

      Erika Jensen-Jarolim, Comparative Medicine, c/o Institute of Pathophysiology and Allergy Research (IPA), Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

      Tel.: 0043-1-40400-5120

      Fax: 0043-1-40400-6188

      E-mail: erika.jensen-jarolim@meduniwien.ac.at

    Search for more papers by this author

  • Edited by: Marek Sanak

Abstract

Passive immunotherapy with monoclonal antibodies is an indispensable cornerstone of clinical oncology. Notably, all FDA-approved antibodies comprise the IgG class, although numerous research articles proposed monoclonal antibodies of the IgM, IgG, IgA and IgE classes directed specifically against tumor-associated antigens. In particular, for the IgE isotype class, several recent studies could demonstrate high tumoricidic efficacy. Therefore, this review specifically highlights the latest developments toward IgE-based immunotherapy of cancer. Possible mechanisms and safety aspects of IgE-mediated tumor cell death are discussed with special focus on the attracted immune cells. An outlook is given on how especially comparative oncology could contribute to further developments. Humans and dogs have a highly comparable IgE biology, suggesting that translational AllergoOncology studies in patients with canine cancer could have predictive value for the potential of IgE-based anticancer immunotherapy in human clinical oncology.

Ancillary